Implications of protease activation in cardiac dysfunction and development of genetic cardiomyopathy in hamsters.
暂无分享,去创建一个
N. Dhalla | L. Hryshko | D. Freed | A. Müller
[1] N. Dhalla,et al. Role of various proteases in cardiac remodeling and progression of heart failure , 2012, Heart Failure Reviews.
[2] F. Sellke,et al. Chymase Inhibition Reduces Infarction and Matrix Metalloproteinase-9 Activation and Attenuates Inflammation and Fibrosis after Acute Myocardial Ischemia/Reperfusion , 2011, Journal of Pharmacology and Experimental Therapeutics.
[3] J. S. Janicki,et al. Tryptase/Protease-Activated Receptor 2 Interactions Induce Selective Mitogen-Activated Protein Kinase Signaling and Collagen Synthesis by Cardiac Fibroblasts , 2011, Hypertension.
[4] H. Granzier,et al. Titin is a Target of Matrix Metalloproteinase-2: Implications in Myocardial Ischemia/Reperfusion Injury , 2010, Circulation.
[5] T. Denney,et al. Chymase Inhibition Prevents Fibronectin and Myofibrillar Loss and Improves Cardiomyocyte Function and LV Torsion Angle in Dogs With Isolated Mitral Regurgitation , 2010, Circulation.
[6] T. Reinheckel,et al. Specialized roles for cysteine cathepsins in health and disease. , 2010, The Journal of clinical investigation.
[7] J. Inserte,et al. Calpain translocation and activation as pharmacological targets during myocardial ischemia/reperfusion. , 2010, Journal of molecular and cellular cardiology.
[8] F. Spinale,et al. Caspase Inhibition Modulates Left Ventricular Remodeling Following Myocardial Infarction Through Cellular and Extracellular Mechanisms , 2010, Journal of cardiovascular pharmacology.
[9] R. Schulz,et al. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. , 2010, Cardiovascular research.
[10] M. Zile,et al. Calpain inhibition preserves myocardial structure and function following myocardial infarction. , 2009, American journal of physiology. Heart and circulatory physiology.
[11] W. Carver,et al. Cardiac Mast Cells Mediate Left Ventricular Fibrosis in the Hypertensive Rat Heart , 2009, Hypertension.
[12] M. Crespo,et al. Early pathophysiological alterations in experimental cardiomyopathy: the Syrian cardiomyopathic hamster. , 2008, Puerto Rico health sciences journal.
[13] H. Kalbacher,et al. Cathepsin D: a cellular roadmap. , 2008, Biochemical and biophysical research communications.
[14] N. Dhalla,et al. Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. , 2008, Cardiovascular research.
[15] F. Marín,et al. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. , 2008, American heart journal.
[16] R. Neumar,et al. Mechanistic Role of Calpains in Postischemic Neurodegeneration , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[17] S. Nishimura,et al. Phosphorylation status of regulatory proteins and functional characteristics in myocardium of dilated cardiomyopathy of Syrian hamsters. , 2008, The journal of physiological sciences : JPS.
[18] Francis G Spinale,et al. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.
[19] B. Turk,et al. Protease signalling in cell death: caspases versus cysteine cathepsins , 2007, FEBS letters.
[20] R. Schulz. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. , 2007, Annual review of pharmacology and toxicology.
[21] Gang Zhao,et al. Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy , 2006, European journal of heart failure.
[22] M. Schellings,et al. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. , 2006, Cardiovascular research.
[23] H. Ushikoshi,et al. Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor. , 2006, The American journal of pathology.
[24] G. Deng,et al. Serine proteases and cardiac function. , 2005, Biochimica et biophysica acta.
[25] T. Ebisawa,et al. A novel scheme of dystrophin disruption for the progression of advanced heart failure. , 2005, Biochimica et biophysica acta.
[26] D. Szczesna‐Cordary,et al. Degradation of Myosin Light Chain in Isolated Rat Hearts Subjected to Ischemia-Reperfusion Injury: A New Intracellular Target for Matrix Metalloproteinase-2 , 2005, Circulation.
[27] N. Dhalla,et al. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin–angiotensin system , 2005, Expert review of cardiovascular therapy.
[28] M. Åbrink,et al. A Key Role for Mast Cell Chymase in the Activation of Pro-matrix Metalloprotease-9 and Pro-matrix Metalloprotease-2* , 2005, Journal of Biological Chemistry.
[29] Y. Ishikawa,et al. Serial Alterations of β-Adrenergic Signaling in Dilated Cardiomyopathic Hamsters , 2004 .
[30] N. Dhalla,et al. Role of proteases in the pathophysiology of cardiac disease , 2004, Molecular and Cellular Biochemistry.
[31] F. Martinon,et al. Inflammatory Caspases Linking an Intracellular Innate Immune System to Autoinflammatory Diseases , 2004, Cell.
[32] S. Takai,et al. An Antiarrhythmic Effect of a Chymase Inhibitor after Myocardial Infarction , 2004, Journal of Pharmacology and Experimental Therapeutics.
[33] S. Doggrell,et al. Vascular chymase: pathophysiological role and therapeutic potential of inhibition. , 2004, Cardiovascular research.
[34] S. Homma,et al. Simvastatin Preserves Cardiac Function in Genetically Determined Cardiomyopathy , 2004, Journal of cardiovascular pharmacology.
[35] S. Chakraborti,et al. Regulation of matrix metalloproteinases: An overview , 2003, Molecular and Cellular Biochemistry.
[36] S. Chakraborti,et al. Structure and evolutionary aspects of matrix metalloproteinases: A brief overview , 2003, Molecular and Cellular Biochemistry.
[37] P. di Nardo,et al. Identification of a new missense mutation in the mtDNA of hereditary hypertrophic, but not dilated cardiomyopathic hamsters , 2003, Molecular and Cellular Biochemistry.
[38] D. Kosior,et al. Tryptase levels in patients after acute coronary syndromes: The potential new marker of an unstable plaque? , 2003, Clinical cardiology.
[39] P. Kovanen,et al. Role for chymase in heart failure: angiotensin II-dependent or -independent mechanisms? , 2003, Circulation.
[40] G. Lip,et al. Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1? , 2003, Stroke.
[41] S. Takai,et al. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. , 2003, Cardiovascular research.
[42] G. Salvesen,et al. Caspases: keys in the ignition of cell death. , 2002, Chemical reviews.
[43] Li-qun Jiang,et al. Transgenic study of the function of chymase in heart remodeling , 2002, Journal of hypertension.
[44] G. Caughey. New developments in the genetics and activation of mast cell proteases. , 2002, Molecular immunology.
[45] S. Takai,et al. Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. , 2002, Life sciences.
[46] K. Wang,et al. The calpain family and human disease. , 2001, Trends in molecular medicine.
[47] T. Ley,et al. Dipeptidyl Peptidase I Is Essential for Activation of Mast Cell Chymases, but Not Tryptases, in Mice* , 2001, The Journal of Biological Chemistry.
[48] F. Spinale,et al. Myocardial remodelling and matrix metallotxoteinases in heart failure: turmoil within the interstitium , 2001, Annals of medicine.
[49] F. Spinale,et al. A Matrix Metalloproteinase Induction/Activation System Exists in the Human Left Ventricular Myocardium and Is Upregulated in Heart Failure , 2000, Circulation.
[50] N. Dhalla,et al. Changes in the expression of cardiac Na+-K+ ATPase subunits in the UM-X7.1 cardiomyopathic hamster. , 2000, Life sciences.
[51] H. Urata. Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease , 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[52] N. Dhalla,et al. Role of oxidative stress in cardiovascular diseases , 2000, Journal of hypertension.
[53] M. Martone,et al. Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters. , 2000, American journal of physiology. Heart and circulatory physiology.
[54] S. Takai,et al. Characterization of recombinant human chymase expressed in Escherichia coli. , 2000, Japanese journal of pharmacology.
[55] S. Miyamoto,et al. Extracellular matrix regulation in the development of Syrian cardiomyopathic Bio 14.6 and Bio 53.58 hamsters. , 1999, Journal of molecular and cellular cardiology.
[56] W. D. De Mello,et al. Correlation between changes in morphology, electrical properties, and angiotensin-converting enzyme activity in the failing heart. , 1999, European journal of pharmacology.
[57] G. Schneider,et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. , 1999, Science.
[58] G. Angelini,et al. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[59] J C Reed,et al. Mitochondria and apoptosis. , 1998, Science.
[60] F. Spinale,et al. Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy , 1998 .
[61] F. Paganelli,et al. Immunological Identification of Na,K‐ATPase Isoforms in Nonfailing and Failing Myocardium a , 1997, Annals of the New York Academy of Sciences.
[62] I. Dixon,et al. Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan. , 1997, Journal of molecular and cellular cardiology.
[63] S. Takai,et al. Chymase is activated in the hamster heart following ventricular fibrosis during the chronic stage of hypertension , 1997, FEBS letters.
[64] A. Fukamizu,et al. Activation of angiotensin II‐forming chymase in the cardiomyopathic hamster heart , 1997, Journal of hypertension.
[65] D. Turk,et al. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. , 1997, Biological chemistry.
[66] S. Kumar,et al. Differential gene expression of extracellular matrix components in dilated cardiomyopathy , 1996, Journal of cellular biochemistry.
[67] S. Tyagi,et al. Role of extracellular matrix metalloproteinases in cardiac remodelling , 1996, Heart Failure Reviews.
[68] S. Takai,et al. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. , 1996, Life sciences.
[69] A. Walls,et al. Regulation of the activity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine. , 1995, Biochimica et biophysica acta.
[70] T. Ogihara,et al. Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters. , 1994, The American journal of physiology.
[71] A. Kobayashi,et al. Possible involvement of free radicals and antioxidants in the early stages of the development of cardiomyopathy in BIO 14.6 Syrian Hamster. , 1991, Japanese heart journal.
[72] K. Weber,et al. Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.
[73] L. Matrisian,et al. Mutational analysis of the transin (rat stromelysin) autoinhibitor region demonstrates a role for residues surrounding the "cysteine switch". , 1991, The Journal of biological chemistry.
[74] K. Misono,et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. , 1990, The Journal of biological chemistry.
[75] J. Scheuer,et al. Troponin-tropomyosin abnormalities in hamster cardiomyopathy. , 1990, The Journal of clinical investigation.
[76] B. Healy,et al. Angiotensin II-forming pathways in normal and failing human hearts. , 1990, Circulation research.
[77] K. Suzuki,et al. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. , 1989, The Journal of clinical investigation.
[78] S. Snyder,et al. Alterations in Calcium Antagonist Receptors and Sodium-Calcium Exchange in Cardiomyopathic Hamster Tissues , 1989, Circulation research.
[79] S. Factor,et al. Intrinsic connective tissue abnormalities in the heart muscle of cardiomyopathic Syrian hamsters. , 1987, The American journal of pathology.
[80] N. Dhalla,et al. Sarcolemmal Na+-Ca2+ exchange during the development of genetically determined cardiomyopathy. , 1985, Biochemical and biophysical research communications.
[81] L. Schwartz,et al. The fibrinogenolytic activity of purified tryptase from human lung mast cells. , 1985, Journal of immunology.
[82] N. Dhalla,et al. Sarcolemmal alterations during the development of genetically determined cardiomyopathy. , 1984, Cardiovascular research.
[83] E. Sonnenblick,et al. HEREDITARY AND ACQUIRED CARDIOMYOPATHIES IN EXPERIMENTAL ANIMALS: MECHANICAL, BIOCHEMICAL, AND STRUCTURAL FEATURES * , 1979, Annals of the New York Academy of Sciences.
[84] E. Sonnenblick,et al. Depressed myosin ATPase activity in hearts of myopathic hamsters: dissociation from neutral protease activity. , 1978, Journal of molecular and cellular cardiology.
[85] J. Dingle,et al. Altered distribution of lysosomal cathepsin D in ischemic myocardium. , 1977, The Journal of clinical investigation.
[86] M. Peach. Renin-angiotensin system: biochemistry and mechanisms of action. , 1977, Physiological reviews.
[87] N. Dhalla,et al. Comparison of heart sarcolemmal enzyme activities in normal and cardiomyopathic (UM-X7.1) hamsters. , 1976, Clinical science and molecular medicine.
[88] R. Schulz,et al. Activation of MMP-2 as a key event in oxidative stress injury to the heart. , 2009, Frontiers in bioscience.
[89] N. Zidar,et al. Caspases in myocardial infarction. , 2007, Advances in clinical chemistry.
[90] M. Crespo,et al. Angiotensin II-dependent vascular alterations in young cardiomyopathic hamsters: role for oxidative stress. , 2006, Vascular pharmacology.